References
Bahrami B, Hong T, Zhu M, Schlub TE, Chang A (2017) Switching therapy from bevacizumab to aflibercept for the management of persistent macular edema. Graefes Arch Clin Exp Ophthalmol. doi:10.1007/s00417-017-3624-y
Freund KB, Korobelnik JF, Deveny R et al (2015) Treat-and extend regimens with anti-VEGF agents in retinal diseases. Retina 35:1489–1506
Gover S, Murthy RK, Brar VS, Chalam KV (2009) Normative data formacular thickness by high-definition spectral-domain optical coherence tomography (spectralis). Am J Ophthalmol 148:266–271
Papadopoulos N, Martin J, Ruan Q et al (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15:171–185
Călugăru D, Călugăru M (2016) Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema. Am J Ophthalmol 168(2):290–291
Călugaru D, Călugăru M (2017) Real-world outcomes of ranibizumab treatment for diabetic macular edema in a United Kingdom National Health Service setting. Am J Ophthalmol 174(2):175–176
Călugăru D, Călugăru M (2017) Ranibizumab for persistent diabetic macular edema after bevacizumab treatment. Eur J Ophthalmol. doi:10.5301/ejo.5000898
Călugăru D, Călugăru M (2016) Comments to: long-term efficacy and safety of intravitreal dexamethasone implant for the treatment of diabetic macular edema. Eur J Ophthalmol 26(6):171–172
Acknowledgements
The authors have full control of the primary data, and they agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data if requested.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
Disclosure
All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No financial disclosures. Both authors (D.C and M.C) were involved in design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript.
Rights and permissions
About this article
Cite this article
Călugăru, D., Călugăru, M. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 255, 1451–1452 (2017). https://doi.org/10.1007/s00417-017-3669-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-017-3669-y